Drug resistance in ovarian cancer — the role of p53
✍ Scribed by Russel Petty; Alan Evans; Iain Duncan; Christian Kurbacher; Ian Cree
- Publisher
- Springer Netherlands
- Year
- 1998
- Tongue
- English
- Weight
- 772 KB
- Volume
- 4
- Category
- Article
- ISSN
- 1219-4956
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract We have examined p53 protein levels in cell lines selected for resistance to the chemotherapeutic drug __cis__‐diamminedichloroplatinum (II), cisplatin. The majority of the independent cisplatin‐resistant clones isolated by a single selection with cisplatin from the ovarian tumour cell
A possible novel mechanism of cross-resistance to cisplatin (CDDP) in the doxorubicin-resistant ovarian-cancer cell line A2780-DX3, which displays atypical multidrug resistance, is presented. A2780-DX3 is found to be more resistant than the parental line A2780 in terms of CDDP-induced cytotoxicity a
## Abstract Resistance to cisplatin‐based chemotherapy is a major cause of treatment failure in human ovarian cancer. Wild‐type __TP53__ status is often, but not always, associated with cisplatin sensitivity, suggesting that additional factors may be involved. Overexpression/activation of the phosp